Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163410
Status:
COMPLETED
Last Update Posted:
2016-12-02
First Post:
2005-09-12
Brief Title:
Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma 4 to 15 y BY9010M1-205
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Comparative Study of Inhaled Ciclesonide 200 mcgDay vs Fluticasone Propionate 200 mcgDay in Children With Asthma
Status:
COMPLETED
Status Verified Date:
2016-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to compare the efficacy of ciclesonide versus fluticasone propionate on lung function symptoms and use of rescue medication in children with persistent asthma Ciclesonide will be inhaled at one dose level once daily fluticasone propionate will be inhaled at one dose level twice daily The study duration consists of a baseline period 2 to 4 weeks and a treatment period 12 weeks The study will provide further data on safety and tolerability of ciclesonide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None